Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance)
- Citation:
- Blood vol 130 (Suppl 1) 485
- Meeting Instance:
- ASH 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3045
- Pharmas:
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Kristie A. Blum Sin-Ho Jung Ian Barak Eric D. Hsi Nancy L. Bartlett James N. Atkins Nina Wagner-Johnston Eric Hsi Bruce D. Cheson John P. Leonard
- Networks:
- CAPITAL, LAPS-MD017, LAPS-MN026, LAPS-MO011, LAPS-OH007, NC002, NY018
- Study
- CALGB-50904
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: